Uracil incorporation into genomic DNA does not predict toxicity caused by chemotherapeutic inhibition of thymidylate synthase.
Thymidylate synthase (TS) is an important target of several chemotherapeutic agents, including 5-FU and raltitrexed (Tomudex). During TS inhibition, TTP levels decrease with a subsequent increase in dUTP. Uracil incorporated into the genome is removed by base excision repair (BER). Thus, BER initiated by uracil DNA glycosylase (UDG) activity has been hypothesized to influence the toxicity induced by TS inhibitors. In this study we created a human cell line expressing the Ugi protein inhibitor of UNG family of UDGs, which reduces cellular UDG activity by at least 45-fold. Genomic uracil incorporation was directly measured by mass spectrometry following treatment with TS inhibitors. Genomic uracil levels were increased over 4-fold following TS inhibition in the Ugi-expressing cells, but did not detectably increase in UNG proficient cells. Despite the difference in genomic uracil levels, there was no difference in toxicity between the UNG proficient and UNG-inhibited cells to folate or nucleotide-based inhibitors of TS. Cell cycle analysis showed that UNG proficient and UNG-inhibited cells arrested in early S-phase and resumed replication progression during recovery from RTX treatment almost identically. The induction of gamma-H2AX was measured following TS inhibition as a measure of whether uracil excision promoted DNA double strand break formation during S-phase arrest. Although gamma-H2AX was detectable following TS inhibition, there was no difference between UNG proficient and UNG-inhibited cells. We therefore conclude that uracil excision initiated by UNG does not adequately explain the toxicity caused by TS inhibition in this model.
Luo
Yuhong
Y
Department of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC 29208, USA.
Walla
Mike
M
Wyatt
Michael D
MD
D015153:Blotting, Western; D000069287:Capecitabine; D002453:Cell Cycle / Q000502:physiology; D002460:Cell Line; D004247:DNA / Q000378:metabolism*; D017931:DNA Primers / Q000235:genetics; D004260:DNA Repair / Q000502:physiology*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000494:pharmacology; D049452:Green Fluorescent Proteins; D006801:Humans; D013058:Mass Spectrometry; D011799:Quinazolines / Q000494:pharmacology; D013876:Thiophenes / Q000494:pharmacology; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors*; D014498:Uracil / Q000032:analysis / Q000378:metabolism*; D051981:Uracil-DNA Glycosidase / Q000037:antagonists & inhibitors* / Q000378:metabolism*
D017931:DNA Primers; D011799:Quinazolines; D013876:Thiophenes; D003841:Deoxycytidine; D049452:Green Fluorescent Proteins; D014498:Uracil; D000069287:Capecitabine; D004247:DNA; D013940:Thymidylate Synthase; D051981:Uracil-DNA Glycosidase; C068874:raltitrexed; D005472:Fluorouracil